|

TTP488 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Azeliragon

Pipeline

Phase 1/2: 1

Top Sponsors

  • Georgetown University1

Indications

  • Cancer Related Cognitive Decline1
  • Non-metastatic Breast Cancer1
  • Breast Cancer1
  • Cancer1

Washington D.C., District of Columbia1 trial

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

Georgetown Lombardi Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.